Advanced Parenteral Closure Solutions

Advanced parenteral closure solutions to comply with a changing market

The pharmaceutical industry is evolving towards more complex and sophisticated drugs such as biologics and next-generation vaccines. These innovations offer new possibilities for treating and preventing various diseases but may involve more complex manufacturing processes and substantial research and development investments.

Alongside this progression, regulatory expectations are also changing, with agencies imposing stricter standards for safety, efficacy, and quality.

Leveraging decades of primary packaging expertise, Aptar Pharma can help our pharmaceutical partners navigate these increasingly complex landscapes. We have developed technologies and processes that can be combined to help you bring safer and more effective therapeutics to patients, reducing the overall risk, while improving your operation and accelerating time-to-market.

A premium approach to ensuring drug integrity and patient safety

As primary packaging is in direct contact with the drug product, its cleanliness is of prime importance. Contamination, whether in the form of fibers, particles or micro-organisms can pose a serious threat to patient safety. Pharmaceutical manufacturers must ensure that their manufacturing operates under the strictest controls from the earliest stages of their supply chain all the way through to the packaging of their finished product and final delivery to the patient.

Aptar Pharma’s advanced parenteral closure solutions have been developed to reduce the risk of contamination and to support the safe delivery of each dose to patients.

• Improved packaging cleanliness with PremiumFill^® delivering improved specifications regarding key contamination criteria including levels of fibers, particulate, and biological matter.
• Sterility is guaranteed at the time of use with Aptar Pharma’s Ready-To-Use (RTU) vial stoppers and pre-filled syringe plungers.
• Prevent contamination of your drug product during fill-finish operations by choosing Rapid Transfer Port (RTP) bags for your advanced parenteral closures.

Improved operational efficiency

With the rising costs associated with drug development and manufacturing, any operational inefficiency, product rejects or eventual product recalls can lead to significant financial losses for pharmaceutical companies. Selecting the right advanced parenteral packaging components can therefore help reduce these risks, ultimately mitigating the total cost of ownership for higher quality packaging and promoting the long term-success for your drug on the market.

• With their improved specifications, including particle contamination limits, PremiumFill^® vial stoppers and pre-filled syringe plungers can help minimize rejection rates on drug product fill-finish lines, reduce scrap rates and lower the overall risk of recalls.
• Ready-to-Use (RTU) syringe plunger and vial stopper solutions guarantee sterility at the time of use and eliminates the need for a drug manufacturer to acquire its own costly sterilization equipment and validate their own sterilization process, thereby saving them time, production space and costs.
• Minimize the risk of accidentally introducing particles to products on your sterile filling line, reducing product rejects and the risk of product recalls.